# Trogenix

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/trogenix

- Industry: Biotechnology
- Headquarters: Edinburgh, UK
- Website: www.trogenix.com
- Total disclosed funding: $110M
- Latest round: Series A (Oct 6, 2025)
- Investors on record: 10

## About

Founded in 2023 and based in the UK, Trogenix Ltd. is engaged in delivering therapies for glioblastoma. In October 2025, Trogenix Ltd raised GBP 70 million in series A funding led by returning investor IQ Capital, with participation from other returning investors 4BIO Capital Partners, National Brain Tumor Society, and Cancer Research Horizons. New investors Eli Lilly and Company Limited, Meltwind, LongeVC, and Calculus Capital, individual and other unspecified investors also participated in the round.


Trogenix engaged in developing therapies targeting glioblastoma through its Odysseus Platform, which is designed to deliver Precision Therapies including Synthetic Super-Enhancers (SSEs). The company’s lead program focuses on treatments that have demonstrated curative potential in preclinical studies. Trogenix's core offerings are tailored for oncologists and healthcare institutions that seek solutions for glioblastoma management. 

Trogenix engages in a structured revenue model predominantly through partnerships with healthcare providers and research institutions, facilitating B2B transactions focused on the advanced treatment of glioblastoma. The company’s revenue generation is anchored in collaborative agreements that may involve milestone payments tied to specific clinical development phases, as well as royalties on future sales of therapies derived from its technology platform. 

The company will use the October 2025 funding to advance its cancer therapy pipeline into clinical trials for multiple aggressive solid tumors.

## Funding rounds

- Series A, Oct 6, 2025, $94M — Lilly Ventures, Calculus Capital, IQ Capital, 4BIO Capital Partners, LongeVC, Brain Tumor Investment Fund, Meltwind Advisory, Cancer Research Horizons
- Seed, Feb 9, 2024, $16M — IQ Capital, Old College Capital, 4BIO Capital Partners, Brain Tumor Investment Fund, AIN Ventures, Cancer Research Horizons

## Investors

- IQ Capital (https://capitalatlas.ai/funds/iq-capital) — Seed, Series A
- Old College Capital (https://capitalatlas.ai/funds/old-college-capital) — Seed
- 4BIO Capital Partners (https://capitalatlas.ai/funds/4bio-capital-partners) — Seed, Series A
- Brain Tumor Investment Fund — Seed, Series A
- AIN Ventures (https://capitalatlas.ai/funds/ain-ventures) — Seed
- Cancer Research Horizons (https://capitalatlas.ai/funds/cancer-research-horizons) — Seed, Series A
- Lilly Ventures (https://capitalatlas.ai/funds/lilly-ventures) — Series A
- Calculus Capital (https://capitalatlas.ai/funds/calculus-capital) — Series A
- LongeVC (https://capitalatlas.ai/funds/longevc) — Series A
- Meltwind Advisory (https://capitalatlas.ai/funds/meltwind-advisory) — Series A